Literature DB >> 19363122

Chronic exposure to fibrin and fibrinogen differentially regulates intracellular Ca2+ in human pulmonary arterial smooth muscle and endothelial cells.

Amy L Firth1, Jocelyn Yau, Amanda White, Peter G Chiles, James J Marsh, Timothy A Morris, Jason X-J Yuan.   

Abstract

Acute pulmonary embolism occurs in more than half a million people a year in the United States. Chronic thromboembolic pulmonary hypertension (CTEPH) develops in approximately 4% of these patients due to unresolved thromboemboli. CTEPH is thus a relatively common, progressive, and potentially fatal disease. One currently proposed theory for the poor resolution advocates that modification of fibrinogen in CTEPH patients causes resistance of emboli to fibrinolysis. The current study investigated the regulation of cytosolic Ca(2+) ([Ca(2+)](cyt)), central to the control of cell migration, proliferation, and contraction, by chronic exposure of pulmonary artery smooth muscle (PASMC) and endothelial (PAEC) cells to fibrinogen and fibrin. Basal [Ca(2+)](cyt) was substantially elevated in PAEC after culture on fibrinogen, fibrin, and thrombin and in PASMC on fibrinogen and fibrin. In PAEC, fibrinogen significantly decreased the peak [Ca(2+)](cyt) transient (P <0.001) without a change in the transient peak width (at 50% of the peak height). This response was independent of effects on the proteinase-activated receptor (PAR) 1. Furthermore, chronic exposure to thrombin, an activator of PAR, significantly reduced the peak agonist-induced Ca(2+) release in PAEC, but increased it in PASMC. The recovery rate of the agonist-induced [Ca(2+)](cyt) transients decelerated in PASMC chronically exposed to fibrin; a small increase of the peak Ca(2+) was also observed. Substantial augmentation of PASMC (but not PAEC) proliferation was observed in response to chronic fibrin exposure. In conclusion, chronic exposure to fibrinogen, fibrin, and thrombin caused differential changes in [Ca(2+)](cyt) in PAEC and PASMC. Such changes in [Ca(2+)](cyt) may contribute to vascular changes in patients who have CTEPH where the pulmonary vasculature is persistently exposed to thromboemboli.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19363122      PMCID: PMC2692802          DOI: 10.1152/ajplung.90412.2008

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  23 in total

Review 1.  2-aminoethoxydiphenyl borate (2-APB) is a reliable blocker of store-operated Ca2+ entry but an inconsistent inhibitor of InsP3-induced Ca2+ release.

Authors:  Martin D Bootman; Tony J Collins; Lauren Mackenzie; H Llewelyn Roderick; Michael J Berridge; Claire M Peppiatt
Journal:  FASEB J       Date:  2002-08       Impact factor: 5.191

2.  Abnormally sialylated fibrinogen gamma-chains in a patient with chronic thromboembolic pulmonary hypertension.

Authors:  Timothy A Morris; James J Marsh; Peter G Chiles; Nick H Kim; Kyle J Noskovack; Marisa M Magana; Ralph A Gruppo; Virgil L Woods
Journal:  Thromb Res       Date:  2006-04-19       Impact factor: 3.944

3.  Plasma Lp(a) levels are increased in patients with chronic thromboembolic pulmonary hypertension.

Authors:  M Ignatescu; K Kostner; G Zorn; M Kneussl; G Maurer; I M Lang; K Huber
Journal:  Thromb Haemost       Date:  1998-08       Impact factor: 5.249

4.  Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension.

Authors:  Fumio Sakamaki; Shingo Kyotani; Noritoshi Nagaya; Nagato Sato; Hideo Oya; Norifumi Nakanishi
Journal:  Chest       Date:  2003-10       Impact factor: 9.410

5.  Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells.

Authors:  Hiroshi Kataoka; Justin R Hamilton; David D McKemy; Eric Camerer; Yao-Wu Zheng; Abby Cheng; Courtney Griffin; Shaun R Coughlin
Journal:  Blood       Date:  2003-07-17       Impact factor: 22.113

6.  Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells.

Authors:  T D Gelehrter; R Sznycer-Laszuk
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

7.  Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension.

Authors:  Diana Bonderman; Johannes Jakowitsch; Bassam Redwan; Helga Bergmeister; Maria-Klara Renner; Heidi Panzenböck; Christopher Adlbrecht; Apostolos Georgopoulos; Walter Klepetko; Meinhard Kneussl; Irene M Lang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-31       Impact factor: 8.311

8.  Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli.

Authors:  I M Lang; J J Marsh; M A Olman; K M Moser; R R Schleef
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

9.  Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension.

Authors:  M A Olman; J J Marsh; I M Lang; K M Moser; B R Binder; R R Schleef
Journal:  Circulation       Date:  1992-10       Impact factor: 29.690

10.  Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor.

Authors:  C A McNamara; I J Sarembock; L W Gimple; J W Fenton; S R Coughlin; G K Owens
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

View more
  6 in total

1.  TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes.

Authors:  Kenshi Yamasaki; Kimberly Kanada; Daniel T Macleod; Andrew W Borkowski; Shin Morizane; Teruaki Nakatsuji; Anna L Cogen; Richard L Gallo
Journal:  J Invest Dermatol       Date:  2010-11-25       Impact factor: 8.551

2.  Bone morphogenetic protein 2 decreases TRPC expression, store-operated Ca(2+) entry, and basal [Ca(2+)]i in rat distal pulmonary arterial smooth muscle cells.

Authors:  Yi Zhang; Wenju Lu; Kai Yang; Lei Xu; Ning Lai; Lichun Tian; Qian Jiang; Xin Duan; Minsheng Chen; Jian Wang
Journal:  Am J Physiol Cell Physiol       Date:  2013-02-27       Impact factor: 4.249

3.  Complement C3 deficiency attenuates chronic hypoxia-induced pulmonary hypertension in mice.

Authors:  Eileen M Bauer; Han Zheng; Suzy Comhair; Serpil Erzurum; Timothy R Billiar; Philip M Bauer
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

4.  Angiostatic factors in the pulmonary endarterectomy material from chronic thromboembolic pulmonary hypertension patients cause endothelial dysfunction.

Authors:  Diana Zabini; Chandran Nagaraj; Elvira Stacher; Irene M Lang; Patrick Nierlich; Walter Klepetko; Akos Heinemann; Horst Olschewski; Zoltán Bálint; Andrea Olschewski
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

5.  Thrombin-mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension.

Authors:  Aiko Ogawa; Amy L Firth; Sanae Ariyasu; Ichiro Yamadori; Hiromi Matsubara; Shanshan Song; Dustin R Fraidenburg; Jason X-J Yuan
Journal:  Physiol Rep       Date:  2013-12-29

6.  Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromboembolic pulmonary hypertension.

Authors:  Jan K Hennigs; Hans Jörg Baumann; Nicole Lüneburg; Gesine Quast; Lars Harbaum; Jan Heyckendorf; Karsten Sydow; Bernhard Schulte-Hubbert; Michael Halank; Hans Klose
Journal:  Sci Rep       Date:  2014-04-28       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.